Drug Profile
Tobramycin/dexamethasone - Eyevance Pharmaceuticals
Alternative Names: Dexamethasone/tobramycin - Alcon; TobraDex; Tobradex AF; TobraDex STLatest Information Update: 27 Mar 2024
Price :
$50
*
At a glance
- Originator Alcon
- Class Aminoglycosides; Anti-inflammatories; Antibacterials; Corticosteroids; Eye disorder therapies; Fluorinated steroids; Glucocorticoids; Pregnadienetriols; Small molecules
- Mechanism of Action Glucocorticoid receptor agonists; Immunosuppressants; Protein 30S ribosomal subunit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Ocular inflammation
Most Recent Events
- 02 Mar 2020 Eyevance Pharmaceuticals launched tobramycin/dexamethasone for Ocular inflammation in USA (Ophthalmic)
- 24 Feb 2020 Eyevance Pharmaceuticals announces intention launch tobramycin/dexamethasone on March 2, 2020
- 16 Oct 2019 Eyevance Pharmaceuticals acquires Tobramycin/dexamethasone from Novartis